Pharmaceuticals

Gastrointestinal Therapeutics Market Growth Analysis 2026–2030 Highlighting Innovation And Competitive Landscape

April 30, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Gastrointestinal Therapeutics Market Expected To Reach Based On Its 2026 Value?

The gastrointestinal therapeutics market has shown substantial expansion in recent times. Its value is anticipated to rise from $42.3 billion in 2025 to $44.72 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. Historically, this growth has been driven by several factors: the restricted availability of biologics and sophisticated gastrointestinal treatments, an uptick in the prevalence of acid reflux and ulcers, a dependency on hospital and clinic-based care, increasing public awareness of digestive health, and the prevailing use of traditional over-the-counter antacids and laxatives.

The gastrointestinal therapeutics market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $55.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast timeframe is attributable to several factors, including the emergence of targeted biologics and immunotherapies, the proliferation of ambulatory surgical centers and diagnostic laboratories, the increasing uptake of oral and intravenous drug delivery systems, greater penetration by online pharmacies, and advancements in probiotics and digestive enzyme formulations. Key trends characterizing this period encompass the growing occurrence of gastrointestinal ailments, heightened utilization of biologics and advanced therapeutic options, the broadening availability of over-the-counter treatments, an escalating emphasis on individualized gastrointestinal care, and the expanding reach of online and retail pharmacy channels.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25768&type=smp

What Factors Are Contributing To The Growth Of The Gastrointestinal Therapeutics Market?

The increasing prevalence of inflammatory bowel diseases is anticipated to propel the expansion of the gastrointestinal therapeutics market going forward. Inflammatory bowel disease (IBD) is defined as a persistent condition that causes inflammation in the digestive tract, primarily encompassing Crohn’s disease and ulcerative colitis. The rise in inflammatory bowel diseases is attributed to genetic susceptibility, which triggers an abnormal immune response to gut microbes. Gastrointestinal therapeutics assist in managing and treating these bowel conditions by targeting the underlying inflammation, regulating digestive functions, and alleviating associated symptoms to improve patient outcomes. For instance, in December 2023, according to the IBD Registry, a UK-based non-profit organization, over 5,300 individuals with inflammatory bowel diseases (IBD) were registered in 2023, marking an increase of more than 3,000 members from 2022. Therefore, the growing incidence of inflammatory bowel diseases is driving the growth of the gastrointestinal therapeutics market.

What Are The Key Segment Divisions In The Gastrointestinal Therapeutics Market Segment Structure?

The gastrointestinal therapeutics market covered in this report is segmented –

1) By Product: Over-The-Counter Gastrointestinal Therapeutics, Prescription-Based Gastrointestinal Therapeutics

2) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

3) By Application: Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Peptic Ulcer Disease, Irritable Bowel Syndrome, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Other End-Users

Subsegments:

1) By Over-The-Counter Gastrointestinal Therapeutics: Antacids, Laxatives, Anti-Diarrheal Agents, Digestive Enzymes, Probiotics, H2-Receptor Antagonists, Simethicone Products

2) By Prescription-Based Gastrointestinal Therapeutics: Proton Pump Inhibitors, Antibiotics For H. pylori, Aminosalicylates, Biologics, Corticosteroids, Immunosuppressants, Antiemetics

What Trends Are Affecting The Direction Of The Gastrointestinal Therapeutics Market?

Major companies in the gastrointestinal therapeutics market are directing their efforts toward creating advanced therapies, such as sustained-release (SR) fixed-dose combination capsules, aiming to enhance patient compliance and boost treatment effectiveness. Sustained-release (SR) fixed-dose combination capsules are oral medications designed to gradually release multiple active ingredients over time, thus maintaining consistent drug levels and reducing dosing frequency. For instance, in June 2024, Akums Drugs and Pharmaceuticals Limited, an India-based pharmaceutical preparation manufacturing company, introduced rabeprazole + levosulpiride SR capsules specifically for treating gastrointestinal disorders in India. This particular formulation brings together rabeprazole, a proton pump inhibitor that works by decreasing stomach acid, and levosulpiride, a prokinetic agent known for improving gut motility. Collaboratively, they provide effective relief from symptoms such as heartburn, acid reflux, bloating, and indigestion. This combination is extensively prescribed for the management of gastroesophageal reflux disease, peptic ulcers, and other associated gastrointestinal (GI) conditions.

Which Organizations Are Engaged In The Gastrointestinal Therapeutics Market?

Major companies operating in the gastrointestinal therapeutics market are Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited., Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Daiichi Sankyo Company Limited., Bausch Health Companies Inc, UCB S.A., Eisai Co. Ltd., Aurobindo Pharma Limited., Dr. Reddy’s Laboratories Limited., Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd., Ferring Pharmaceuticals A/S, Jubilant Pharma Limited., Sebela Pharmaceuticals Inc, Cosmo Pharmaceuticals N.V., Tillotts Pharma AG, Mitsubishi Tanabe Pharma Corporation

Get The Full Gastrointestinal Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

Where Is The Gastrointestinal Therapeutics Market Primarily Concentrated By Region?

North America was the largest region in the gastrointestinal therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastrointestinal therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastrointestinal Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastrointestinal-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Gastrointestinal Therapeutics Market 2026, By The Business Research Company

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Digestive And Intestinal Remedies Market Report 2026

https://www.thebusinessresearchcompany.com/report/digestive-and-intestinal-remedies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795